Genomic Data Management for Precision Medicine: HealthTech market to watch in 2025
- Lloyd Price
- Jun 4
- 4 min read
Genomic Data Management in Precision Medicine
The HealthTech market for Genomic Data Management in Precision Medicine is poised for significant growth in 2025, driven by the increasing demand for personalized healthcare and advancements in genomic technologies.
The global precision medicine market, which heavily relies on genomic data, is projected to grow from $191.31 billion in 2024 to $207.80 billion by 2032, with a CAGR of 10.8%. This growth is fuelled by the rising prevalence of chronic diseases, such as cancer and cardiovascular conditions, where genomics plays a pivotal role in tailoring treatments.
Genomic data management is critical for precision medicine, as it involves handling vast, heterogeneous datasets from sources like Next-Generation Sequencing (NGS). These datasets are often spread across multiple repositories, in various formats, and require robust systems to ensure quality and usability.
The integration of big data analytics, artificial intelligence (AI), and machine learning is transforming this space by enabling faster analysis and interpretation of genomic data, which is essential for identifying disease-specific biomarkers and developing targeted therapies.
A key trend in 2025 is the adoption of cloud-native genomic workflows, which are becoming a competitive edge for R&D and data science teams in precision medicine. These platforms address challenges like large file sizes, incompatible formats, and siloed teams, which have historically slowed progress.
Additionally, the market is seeing increased investment in pharmacogenomics data integration platforms, which are expected to grow at an 18% CAGR, driven by the need to harmonise genetic, clinical, and pharmaceutical data for personalised treatment strategies.
North America dominates the market, holding a 53.62% share in 2023, due to strong government support and advancements in genomic research. However, Asia Pacific is expected to grow rapidly, with initiatives like the Genome Asia 100K project aiming to sequence 100,000 Asian genomes to enhance population-specific precision medicine.
Despite the promise, challenges remain, including the high cost of genomic testing infrastructure and the complexity of integrating genomic data into electronic health records (EHRs), which often lack compatibility with genetic data formats.
Genomic Data Management for Precision Medicine market
The Genomic Data Management for Precision Medicine market in 2025 is driven by companies leveraging advanced technologies like Next-Generation Sequencing (NGS), AI, and cloud-based platforms to manage and analyse vast genomic datasets. Here are some leading players in the US, UK, and Europe:
United States:
Illumina, Inc.: A global leader in genomic sequencing, Illumina provides NGS solutions and tools like the TruSight Oncology Comprehensive kit, widely used for comprehensive genomic profiling in precision medicine. They dominate the market with their sequencing technology, essential for personalized therapies.
Thermo Fisher Scientific, Inc.: Known for its Clinical Next-Generation Sequencing and Oncology segment, Thermo Fisher collaborates with entities like Genomics England to advance liquid biopsies for cancer, enhancing genomic data applications in precision medicine.
Tempus: This company uses AI and machine learning to analyze clinical and molecular data, offering solutions that integrate genomic data into personalized treatment strategies, particularly in oncology.
United Kingdom:
Genomics England: A national asset, Genomics England collaborates with the NHS to integrate whole-genome sequencing into routine care. Their partnership with IQVIA has created a Real-World research platform, connecting clinical and genomic data to advance precision medicine research.
Congenica: Specialising in clinical genome analysis, Congenica’s Sapientia platform uses machine learning to produce diagnostic reports from genomic data, supporting precision medicine applications in hospitals across the UK and Europe.
Eagle Genomics: A key player in genomic data management, Eagle Genomics focuses on bioinformatics solutions, helping pharmaceutical companies and research institutions manage and interpret genomic data for precision medicine.
Europe:
Qiagen (Germany): Qiagen is a major player in molecular testing, with a Centre of Excellence in Manchester, UK, for companion diagnostics in precision medicine. Their QIAseq xHYB portfolio supports comprehensive genomic profiling, and they’re expanding in the NGS market.
Sophia Genetics (Switzerland): This company applies AI to genomic data, offering a platform that analyzes DNA sequences to identify mutations for diseases like cancer, improving diagnostic accuracy in precision medicine.
Eurofins Genomics (Part of Eurofins Scientific Group, Luxembourg): A significant player in the NGS market, Eurofins provides genomic sequencing technologies to over 20,000 customers worldwide, supporting precision medicine through large-scale genomic data management.
These companies are at the forefront of integrating genomic data into precision medicine, addressing challenges like data complexity and interoperability while driving innovation in personalized healthcare. However, the high costs of genomic testing and data storage remain hurdles, particularly in Europe, where adoption lags behind the US due to funding and infrastructure gaps.
Nelson Advisors > Healthcare Technology M&A
.
Nelson Advisors specialise in mergers, acquisitions & partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk
Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital
We share our views on the latest Healthcare Technology mergers, acquisitions & partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb
Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk
#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide
Nelson Advisors LLP
Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT
Contact Us
Meet Us
Digital Health Rewired > 18-19th March 2025
NHS ConfedExpo > 11-12th June 2025
HLTH Europe > 16-19th June 2025
コメント